# Nuclide record aktis-oncology (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/aktis-oncology/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "aktis-oncology" ;
  schema:name "Aktis Oncology"@en ;
  schema:description "Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3."@en ;
  schema:url <https://nuclide.cc/companies/aktis-oncology/>, <https://www.aktisoncology.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering> ;
  nuclide:tag "frontier" ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/nectin4/>, <https://nuclide.cc/targets/b7h3/> .